Adjunctive treatment of behavioral disorders in patients with cognitive deficit
Authors:
Ivana Tašková
Authors‘ workplace:
Ústav aplikované farmacie, Farmaceutická fakulta, Masarykova univerzita, Brno
; Oddělení klinické farmacie, Psychiatrická nemocnice Bohnice, Praha
Published in:
Čes. slov. Farm., 2024; 73, 245-250
Category:
For the Practice of a Clinical Pharmacist
doi:
https://doi.org/10.36290/csf.2024.043
Overview
Adjunctive treatment of behavioral disorders in patients with cognitive deficit
The article provides an overview of the pharmacotherapy of behavioural and psychological symptoms of dementia (BPSD) in the context of evidence-based medicine. Its goal is to provide readers with a practical and educational overview of managing these symptoms. Cognitive disorders, including dementia, result from the disruption of higher cortical functions of the brain. Dementia often manifests not only through cognitive dysfunction but also through BPSD, such as agitation, aggression, anxiety, psychosis, and sleep disturbances. These symptoms affect up to 97% of patients with dementia and significantly reduce the quality of life for both patients and caregivers. BPSD are often more stressful for patients and caregivers than the cognitive symptoms themselves.
Behavioural symptoms include a wide range of manifestations from non-aggressive forms such as pacing and repetitive movements to aggressive and agitated behaviour (verbal and physical). Psychological symptoms can include depression, anxiety, and psychotic symptoms such as paranoia and delusions.
The causes of BPSD can be varied, as well as their risk factors (including e.g. co-medication, comorbidities, the patient’s personality traits, inappropriate communication by caregivers, and environmental influences). The pharmacotherapy of BPSD is complex and often involves the use of antipsychotics, antidepressants, benzodiazepines, or acetylcholinesterase inhibitors and memantine. Due to the diversity of manifestations and causes of BPSD, a unified pharmacotherapeutic approach cannot be applied. Non-pharmacological approaches should always be preferred, except in cases of severe depression, psychosis, or aggression that may endanger the patient or someone else. In practice, many medications indicated for BPSD therapy are used off-label. The pharmacotherapy of BPSD should only begin after ruling out other causes of BPSD. Furthermore, it should only be initiated after considering all risks and potential benefits, starting with low geriatric doses, monitoring side effects, regularly reassessing effectiveness, and administering medications for the shortest possible duration should be also applied.
Keywords:
behavioural and psychological symptoms of dementia – psychopharmacology – dementia.
Sources
1. Mohr P, et al. Klinická psychofarmakologie. 2017. Praha: Maxdorf. ISBN: 978-80-7345-546-0.
2. Tašková I. Kognitivní poruchy vyvolané medikací II. Remedia. 2023;33(4):1-7.
3. Holmerová I, et al. Poruchy kognitivních funkcí u starších pacientů. Kap Kardiol. 2012;4:24-27.
4. Bartoš A. Kogitivní funkce, soběstačnost a kognitivní syndromy. Psychiatrie pro praxi. 2022;23(2):91-97.
5. Rektorová I. Neurodegenrativní demence. Česká a slovenská neurologie a neurochirurgie. 2009;72/105(2):97-109.
6. Blazer DG et Schultz SK. (2018). Geriatric Psychiatry. Clinical Review Articles. Psychiatric Clinics of North America. Philadelphia: Elsevier. ISBN: 978-0-323-58170-7.
7. Tašková I, et al. (2021). Psychofarmaka v kazuistikách. 1. vydání. Praha: Maxdorf jesenius. ISBN: 978-80-7245-678-8.
8. Korábečný J, et al. (2020). Alzheimerova nemoc. Praha: Maxdorf. ISBN: 978-80-7345-643-6.
9. Jirák R. Poruchy chování a nálady u demencí. Psychiatrie pro praxi. 2011;12(2):56-60.
10. Taylor D, et al. (2018).The Maudsley Prescribing Guidelines in Psychiatry, 13. vydání. London: Wiley Blackwell.
11. Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311-320.
12. Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):80-97. doi: 10.1080/07853890.2021.2017474. PMID: 34955074; PMCID: PMC8725830.
13. Rahman AA, He N, Rej S, et al. Concomitant Use of Selective Serotonin Reuptake Inhibitors and Oral Anticoagulants and Risk of Major Bleeding: A Systematic Review and Meta-analysis. Thromb Haemost. 2023 Jan;123(1):54-63. doi: 10.1055/a-1932-8976. Epub 2022 Aug 29. PMID: 36037829.
14. Ali A, Siddiqui AA, Ali M, et al. Meta-analysis on performance of ABC and GARFIELD-AF compared to CHA2DS2-VASc and HAS-BLED in anticoagulated atrial fibrillation patients. Cardiovasc Revasc Med. 2023 Oct 12:S1553-8389(23)00848-5. doi: 10.1016/j.carrev.2023. 10. 007. Epub ahead of print. PMID: 37880043.
15. Gao X, Cai X, Yang Y, et al. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021 Nov 22;8:757087. doi: 10.3389/fcvm.2021.757087. PMID: 34881309; PMCID: PMC8648046.
16. Stahl MS. (2013). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practial Applications (4th ed.). Cambridge: Cambridge University Press. ISBN: 978-1-107-68646-5.
17. Hsu WT, Esmaily-Fard A, Lai CC, et al. Antipsychotics and the Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis of Observational Studies. J Am Med Dir Assoc. 2017 Aug 1;18(8):692-699. doi: 10.1016/j.jamda.2017. 02. 020. Epub 2017 Apr 18. PMID: 28431909.
18. CDPC 2015: Laver K, Cummin RG, Dyer SM, et al. Clinical practice guidelines for dementia in Australia. Med J Aust. 2016;204(5):191-193. Available from https://cdpc.sydney.edu.au/wp-content/uploads/2019/06/CDPC-Dementia-Guidelines_WEB.pdf
19. S3-Leitlinie „Demenzen“ (Langversion – Januar 2016). Available from https://dnvp9c1uo2095.cloudfront.net/cms-content/S3-Leitlinie_Demenzen_Langversion_2023_11_28_Final_1701248604534.pdf
20. Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2. PMID: 34918337; PMCID: PMC8678509.
21. Zangani C, Giordano B, Stein HC, et al. Efficacy of tiapride in the treatment of psychiatric disorders: A systematic review. Hum Psychopharmacol. 2022 Sep;37(5):e2842. doi: 10.1002/hup.2842. Epub 2022 Mar 21. PMID: 35313032.
22. Roger M, Gerard D, Leger JM. Intérêt du tiapride dans les états d’agitation du sujet âgé. Revue des études publiées [Value of tiapride for agitation in the elderly. Review of published studies]. Encephale. 1998 Sep-Oct;24(5):462-8. French. PMID: 9850821
23. Allain H, Dautzenberg PH, Maurer K, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl). 2000 Mar;148(4):361-6. doi: 10.1007/s002130050064. PMID: 10928308.
24. Jirák R. Farmakoterapie neklidu u demencí. Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP, 2018. Available from https://postupy-pece.psychiatrie.cz/specialni-psychiatrie/demence/farmakoterapie-neklidu.
25. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Erratum in: Lancet. 2019 Sep 14;394(10202):918. PMID: 31303314; PMCID: PMC6891890.
26. Wijdicks FME. Neuroleptic malignant syndrome. UpToDate. Available from www.uptodate.com.
27. Wu CC, Liao MH, Su CH, Poly TN, Lin MC. Benzodiazepine Use and the Risk of Dementia in the Elderly Population: An Umbrella Review of Meta-Analyses. J Pers Med. 2023 Oct 12;13(10):1485. doi: 10.3390/jpm13101485. PMID: 37888096; PMCID: PMC10608561.
28. Ferreira P, Ferreira AR, Barreto B, Fernandes L. Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews. Eur Geriatr Med. 2022 Feb;13(1):19-32. doi: 10.1007/s41999-021-00553-w. Epub 2021 Aug 17. PMID: 34403113.
29. Zhong G, Wang Y, Zhang Y, Zhao Y. Association between Benzodiazepine Use and Dementia: A Meta-Analysis. PLoS One. 2015 May 27;10(5):e0127836. doi: 10.1371/journal.pone.0127836. PMID: 26016483; PMCID: PMC4446315.
30. Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin P, Chenoweth L, Gorman M, Quirke L, Bethune G, Forbes F, Hilmer S. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Sydney: The University of Sydney; 2018. The full guideline and supporting documents are available at: http://sydney.edu.au/medicine/cdpc/resources/deprescribing-guidelines.php.
31. Clodomiro A, Gareri P, Puccio G, et al. Somatic comorbidities and Alzheimer’s disease treatment. Neurol Sci. 2013 Sep;34(9):1581-9. doi: 10.1007/s10072-013-1290-3. Epub 2013 Feb 1. PMID: 23370896; PMCID: PMC3784058.
32. Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD). Summary document for Primary Care Produced November 2017 review date November 2020. Available from: https://lancsmmg.nhs.uk/media/1064/27-guidelines-for-bpsd-full-document-revised-may-2022.pdf.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2024 Issue 4
Most read in this issue
- Pharmacotherapy of chronic heart failure – essential summary for pharmacists
- Management of gastrointestinal side effects of cancer pharmacotherapy: Part 1: Diarrhoea, constipation, mucositis and anorexia
- Adjunctive treatment of behavioral disorders in patients with cognitive deficit
- Pharmaceutical care for patients with sore throat not requiring medical attention